Daihan Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	209,001	204,195	195,911	184,268	171,463	166,080
Other Revenue	-	-	-	-	-0	-
Revenue	209,001	204,195	195,911	184,268	171,463	166,080
Revenue Growth (YoY)	3.48%	4.23%	6.32%	7.47%	3.24%	-1.59%
Cost of Revenue	140,428	134,788	130,599	124,455	115,781	109,885
Gross Profit	68,574	69,407	65,312	59,812	55,682	56,195
Selling, General & Admin	28,993	28,428	26,945	25,445	24,923	24,892
Research & Development	2,082	1,802	1,641	567.87	790.59	689.17
Amortization of Goodwill & Intangibles	-	-	-	-	0.5	2.89
Other Operating Expenses	462.31	479.63	411.75	387.26	334.4	303.68
Operating Expenses	32,223	31,327	29,517	26,844	26,614	26,232
Operating Income	36,351	38,081	35,795	32,968	29,068	29,963
Interest Expense	-3.67	-1.81	-52.47	-593.43	-469.27	-617.06
Interest & Investment Income	1,728	1,475	87.18	486.66	506.7	421.05
Currency Exchange Gain (Loss)	885.74	1,229	504.71	525.35	687.03	-426.96
Other Non Operating Income (Expenses)	44.64	1,184	87.57	73.92	599.56	822.93
EBT Excluding Unusual Items	39,006	41,967	36,422	33,461	30,392	30,163
Gain (Loss) on Sale of Investments	485.59	303.6	288.69	-	-	-
Gain (Loss) on Sale of Assets	48.97	58.03	22.53	-9.4	41.28	19.72
Asset Writedown	-	-	-	-	-	-7,650
Pretax Income	39,541	42,329	36,734	33,451	30,433	22,532
Income Tax Expense	7,984	8,569	8,307	8,491	7,763	5,151
Net Income	31,556	33,759	28,426	24,961	22,670	17,381
Net Income to Common	31,556	33,759	28,426	24,961	22,670	17,381
Net Income Growth	2.91%	18.76%	13.88%	10.10%	30.43%	-38.29%
Shares Outstanding (Basic)	6	6	6	6	6	6
Shares Outstanding (Diluted)	6	6	6	6	6	6
Shares Change (YoY)	-	-	-1.75%	-0.25%	-	-
EPS (Basic)	5366.74	5741.34	4834.41	4170.67	3778.40	2896.80
EPS (Diluted)	5366.74	5741.34	4834.41	4170.67	3778.40	2896.80
EPS Growth	2.91%	18.76%	15.92%	10.38%	30.43%	-38.29%
Free Cash Flow	4,207	19,841	17,580	20,378	28,767	28,267
Free Cash Flow Per Share	715.47	3374.38	2989.79	3405.01	4794.57	4711.20
Gross Margin	32.81%	33.99%	33.34%	32.46%	32.48%	33.84%
Operating Margin	17.39%	18.65%	18.27%	17.89%	16.95%	18.04%
Profit Margin	15.10%	16.53%	14.51%	13.55%	13.22%	10.46%
Free Cash Flow Margin	2.01%	9.72%	8.97%	11.06%	16.78%	17.02%
EBITDA	44,518	45,362	44,459	42,176	40,479	41,263
EBITDA Margin	21.30%	22.21%	22.69%	22.89%	23.61%	24.85%
D&A For EBITDA	8,166	7,282	8,663	9,208	11,411	11,300
EBIT	36,351	38,081	35,795	32,968	29,068	29,963
EBIT Margin	17.39%	18.65%	18.27%	17.89%	16.95%	18.04%
Effective Tax Rate	20.19%	20.24%	22.61%	25.38%	25.51%	22.86%
Advertising Expenses	-	99.76	78.69	93.67	63.18	48.89

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.